SIGLEC6 Human

Sialic Acid Binding Ig Like Lectin 6 Human Recombinant
Cat. No.
BT26355
Source

Sf9, Baculovirus cells.

Synonyms

Sialic Acid Binding Ig Like Lectin 6, Obesity-Binding Protein 1, CD33 Antigen-Like 1, CDW327, CD33L1, CD33L, OBBP1, Sialic Acid Binding Ig-Like Lectin 6, Sialic Acid-Binding Ig-Like Lectin 6, CD327 Antigen, Siglec-6, CD33L2, OB-BP1, CD327, SIGLEC6.

Appearance
Sterile filtered colorless solution.
Purity

Greater than 90.0% as determined by SDS-PAGE.

Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

SIGLEC6 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 563 amino acids (27-347a.a.) and having a molecular mass of 62.6kDa (Molecular size on SDS-PAGE will appear at approximately 70-100kDa). SIGLEC6 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
Sialic acid-binding Ig-like lectin 6 isoform 1 (SIGLEC6) is a member of the immunoglobulin superfamily and SIGLEC (sialic acid-binding Ig-like lectin) family. SIGLEC6 mediates sialic-acid-dependent binding to cells and binds to alpha-2, 6-linked sialic acid. This protein is found in numerous cellular compartments, including the membrane fraction and extracellular region. The SIGLEC6 receptor binds sialyl-TN glycans and leptin. Placental SIGLEC6 expression is upregulated in preeclampsia.
Description
Recombinant human SIGLEC6, produced in Sf9 Baculovirus cells, is a single, glycosylated polypeptide chain containing 563 amino acids (27-347a.a.) with a molecular mass of 62.6 kDa. Note: SDS-PAGE analysis of this protein will appear at approximately 70-100 kDa due to glycosylation. SIGLEC6 is expressed with a 239 amino acid hIgG-His tag at the C-terminus and purified by proprietary chromatographic techniques.
Physical Appearance
Sterile filtered, colorless solution.
Formulation
SIGLEC6 protein solution (0.5 mg/ml) is supplied in Phosphate Buffered Saline (pH 7.4) with 10% glycerol.
Stability
For short-term storage (2-4 weeks), store at 4°C. For long-term storage, store at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity
Greater than 90.0% purity as determined by SDS-PAGE.
Synonyms

Sialic Acid Binding Ig Like Lectin 6, Obesity-Binding Protein 1, CD33 Antigen-Like 1, CDW327, CD33L1, CD33L, OBBP1, Sialic Acid Binding Ig-Like Lectin 6, Sialic Acid-Binding Ig-Like Lectin 6, CD327 Antigen, Siglec-6, CD33L2, OB-BP1, CD327, SIGLEC6.

Source

Sf9, Baculovirus cells.

Amino Acid Sequence

ADLQERRFQL EGPESLTVQE GLCVLVPCRL PTTLPASYYG YGYWFLEGAD VPVATNDPDE EVQEETRGRF HLLWDPRRKN CSLSIRDARR RDNAAYFFRL KSKWMKYGYT SSKLSVRVMA LTHRPNISIP GTLESGHPSN LTCSVPWVCE QGTPPIFSWM SAAPTSLGPR TTQSSVLTIT PRPQDHSTNL TCQVTFPGAG VTMERTIQLN VSYAPQKVAI SIFQGNSAAF KILQNTSSLP VLEGQALRLL CDADGNPPAH LSWFQGFPAL NATPISNTGV LELPQVGSAE EGDFTCRAQH PLGSLQISLS LFVHWKPEGR AGGVLEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGKHHH HHH.

Product Science Overview

Introduction

Sialic Acid Binding Ig Like Lectin 6 (Siglec-6) is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. These are cell surface proteins predominantly expressed on immune cells and play a crucial role in modulating immune responses. Siglec-6, in particular, has garnered attention due to its potential implications in immunotherapy and its unique expression profile.

Structure and Function

Siglec-6 is a protein-coding gene associated with the innate immune system and antigen processing pathways . It is characterized by its ability to bind sialic acids, which are a type of sugar molecule found on the surface of cells. This binding capability allows Siglec-6 to interact with other cells and modulate immune responses.

Expression and Role in Disease

Siglec-6 is not widely expressed in healthy tissues, making it an attractive target for therapeutic interventions. Its expression has been noted in certain cancers, including chronic lymphocytic leukemia (CLL), where it serves as a novel target for immunotherapy . The absence of Siglec-6 in most healthy cells and tissues reduces the risk of off-target effects, which is a significant advantage in developing targeted therapies.

Therapeutic Potential

Recent studies have highlighted the potential of Siglec-6 as a target for cancer immunotherapy. For instance, patient-derived antibodies targeting Siglec-6 have shown promise in recruiting T-cells to eliminate cancer cells . These antibodies can be engineered into bispecific antibodies that bind both Siglec-6 and CD3, enhancing their therapeutic efficacy .

Research and Development

Ongoing research aims to further understand the role of Siglec-6 in the immune system and its potential as a therapeutic target. Studies have demonstrated that targeting Siglec-6 can activate T-cells and kill Siglec-6 positive target cells, providing a foundation for developing new cancer treatments .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.